Major depressive disorder trials recruiting in Florida
All Major depressive disorder trials nationally
18
Recruiting in Florida
31
Cities with sites
Cities in Florida
Miami 11Orlando 9Tampa 9Jacksonville 7Hialeah 5Hollywood 4Maitland 4Miami Gardens 4Riverview 3Brandon 2Clermont 2Palm Bay 2
Recruiting trials in Florida
- A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
- A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
- A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
- A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
- A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
- A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Causal Role of Delta-beta Coupling for Goal-directed Behavior in Anhedonic Depression
- Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
- Study of ALTO-300 in MDD
- Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
- Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
- Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics
- Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder